Antibody Therapeutics for Life

Notices


No Title Written by Written date Inquire
16   PharmAbcine`s ``BI(Business Incubation) Research Grant`` proposal is granted by KIAT.   관리자   2019-01-14   49  
15   Dr. Jin-San Yoo, CEO of PharmAbcine is invited to present for ``Investor Relation`` at MIRAE ASSET DAEWOO SECURITIES Corporate Day on July 12th, 2017.   관리자   2019-01-14   50  
14   Interview of Dr. Jin-San Yoo, CEO of PharmAbcine with Bio-Pod   관리자   2019-01-14   53  
13   Dr. Jin-San Yoo, CEO of PharmAbcine is presenting at the forum for future pharm in Seoul on June 23, 2017.   관리자   2019-01-14   55  
12   Dr. Jin-San Yoo, CEO of PharmAbcine is presenting PharmAbcine`s R&D progress and the interim data of the ongoing phase IIa recurrent GBM trial at 2017 Bio International Convention in San Diego on June 19-22, 2017.   관리자   2019-01-14   56  
11   Dr. Lawrence Cher, principle investigator of Tanibirumab phase IIa recurrent GBM trial in Australia expose the interim data of the ongoing trial at ASCO 2017 Annual Meeting in Chicago on June 2-6, 2017.   관리자   2019-01-14   55  
10   Dr. Jin-San Yoo, CEO of PharmAbcine is invited to present PharmAbcine`s R&D progress at BIO LOGISTICS WORLD KOREA in Seoul on May 23-24, 2017.   관리자   2019-01-14   52  
9   Dr. Jin-San Yoo, CEO of PharmAbcine is serving as an expert of MAB working group of EDQM observer representing Republic of Korea.   관리자   2019-01-14   51  
8   Dr. Jin-San Yoo, CEO of PharmAbcine is serving as an officer for Bio at the Med term Strategy and planning for pharma industry.   관리자   2019-01-14   52  
7   Dr. Jin-San Yoo, CEO of PharmAbcine will be awarded for the contribution of Health-Medical by KHIDI President on April 13th, 2017.   관리자   2019-01-14   50